DDInter542 DDInter1082
Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K. In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases.
Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist used in the treatment of type II diabetes mellitus (T2DM). It is sold by Sanofi-Aventis under the brand name Adlyxin in the US and Lyxumia in the EU. Adlyxin recieved FDA approval July 28, 2016.
Dicoumarol {u} (Compound) resembles {v} (Compound) Phenprocoumon
Dicoumarol {u} (Compound) binds {v} (Gene) CYP2C9
Dicoumarol {u} (Compound) downregulates {v} (Gene) P4HTM
Dicoumarol (Compound) resembles Phenprocoumon (Compound)
Dicoumarol (Compound) binds CYP2C9 (Gene)
Dicoumarol (Compound) downregulates P4HTM (Gene)